Given the expression pattern of CD226 and CD28 on CD8+ T cell subsets that likely contribute to a robust response against tumors, optimal activation of the full repertoire of tumor-reactive CD8+ T cells is thus likely to require the coordinate inhibition of both TIGIT and PD-1. The gene discussed is PDCD1; the disease is neoplasm.